Skip to Main Content
Contributors
++

PETER C. ALBERTSEN, MD, Division of Urology, University of Connecticut Health Center, Farmington, Connecticut, USA

++

OMAR AL-SALIHI, BSc MBBS MRCP FRCR, Consultant Oncologist, University College London Hospital, London, UK

++

ANDREW J. ARMSTRONG, MDScM, Duke Comprehensive Cancer Center, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA

++

DENISE C. BABINEAU, PhD, Assistant Staff, Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA

++

DAVID G. BOSTWICK, MD MBA FCAP, CEO, President, Medical Director, Bostwick Laboratories, Glen Allen, Virginia, USA

++

JAMES D. BROOKS, MD, Associate Professor, Department of Urology, Stanford University School of Medicine, Stanford, California, USA

++

ARTHUR L. BURNETT, MD, Department of Urology, Johns Hopkins Hospital, Baltimore, Maryland, USA

++

MICHAEL A. CARDUCCI, MD ScM, Associate Professor of Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

++

STEVEN L. CHANG, MD, Department of Urology, Stanford University School of Medicine, Stanford, California, USA

++

KIM N. CHI, MD FRCP[C], Assistant Professor, Department of Medicine, Division of Medical Oncology, University of British Columbia, Medical Director-Vancouver Centre Clinical Trials Unit, BC Cancer Agency, Vancouver, British Columbia, Canada

++

CHRISTOPHER FARNHAM, MB BS BSc FRCP, Consultant in Palliative Care, St John’s Hospice, Hospital of St John and St Elizabeth, London, UK

++

MARK R. FENELEY, MD(Cantab) FRCS(Eng) FRCS(Urol), Senior Lecturer in Urological Oncological Surgery, University College London, London, UK

++

ADRIAN C. GARDNER, FRCS, Specialist Registrar in Orthopaedics and Trauma, Royal Orthopaedic Hospital NHS Trust, Birmingham, UK

++

ROBERT H. GETZENBERG, PhD, Director of Urology Research, Professor, Urology and Oncology, The Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA

++

DAVID GILLAT, ChM FRCS, Consultant Urologist, The Cotswold Centre, Southmead, Bristol, UK

++

MARTIN E. GLEAVE, MD FRCS[C], Professor, Department of Urological Sciences, University of British Columbia, Director of Research, The Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada

++

MICHAEL W. KATTAN, PhD, Chairman, Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA

++

BRUCE R. KAVA, MD, Department of Urology, University of Miami Miller School of Medicine, Miami, Florida, USA

++

VINCENT KHOO , MBBS FRACR FRCR MD, Consultant and Honorary Senior Lecturer in Clinical Oncology, Department of Radiotherapy and Oncology, Royal Marsden Hospital & Institute of Cancer Research, London, UK

++

ROGER S. KIRBY, MA MD FRCS (Urol), The Prostate Centre, London, UK

++

LAURENCE KLOTZ, MD FRCSC, Chief, Division of Urology, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada

++

EDDY S. LEMAN, PhD, The Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA

++

FAYE LIM, MB BS BSc MRCP, Specialist Registrar in Oncology, University College London Hospital, London, UK

++

SARAH MARIETTI, MD, Division of Urology, University of Connecticut Health Center, Farmington, Connecticut, USA

++

ISABELLE MEIERS, MD, Bostwick Laboratories, Regents Park, London, UK

++

ANITA MITRA, MBBS MRCP FRCR, Clinical Research Fellow, Institute of Cancer Research, Sutton, UK

++

DON NEWLING, MBBChir. FRCS, Medical Director (Oncology), AstraZeneca, Alderley Park, Macclesfield, UK

++

ALAN M. NIEDER, MD, Department of Urology, University of Miami Miller School of Medicine, Miami, Florida, USA

++

JOE O’SULLIVAN, MD FRCPI FFRRCSI, Consultant/Senior Lecturer in Oncology, The Northern Ireland Cancer Centre, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast City Hospital, Belfast, UK

++

HEATHER A. PAYNE, MB BS FRCP RRCR, Consultant Oncologist, Meyerstein, Institute of Urology, University College London, London, UK

++

COLIN PURCELL, MB MRCP, Specialist Registrar in Medical Oncology, The Northern Ireland Cancer Centre, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast City Hospital, Belfast, UK

++

MARK S. SOLOWAY, MD, Professor and Chairman, Department of Urology, University of Miami Miller School of Medicine, Miami, Florida, USA

++

ALISTAIR J. STIRLING, FRCS, Consultant Spinal Surgeon, Royal Orthopaedic Hospital NHS Trust, Birmingham, UK

++

ROGER M. TILMAN, FRCS, Consultant Orthopaedic Oncologist, Royal Orthopaedic Hospital NHS Trust, Birmingham, UK

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.